Cargando…

The Safety and Efficacy of Rituximab-Based Regimen in Atypical Membranous Nephropathy: A Single Center Retrospective Cohort Study

PURPOSE: There are increasing reports of atypical membranous nephropathy (AMN) cases with similar pathological characteristics to secondary membranous nephropathy (SMN) without definite underlying causes. Although rituximab has become a first-line option in treating idiopathic membranous nephropathy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yanan, Zhang, Shuo, Hu, Rongrong, Li, Chao, Chen, Gang, Shi, Xiaoxiao, Liu, Yan, Zheng, Ke, Li, Hang, Wen, Yubing, Li, Xuemei, Li, Xuewang, Xia, Peng, Qin, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224685/ https://www.ncbi.nlm.nih.gov/pubmed/37251282 http://dx.doi.org/10.2147/IJGM.S410169

Ejemplares similares

Rituximab in patients with membranous nephropathy and kidney insufficiency
por: Guo, Yanhong, et al.
Publicado: (2022)

Statins can benefit patients with primary membranous nephropathy on venous thromboembolism
por: Zou, Peimei, et al.
Publicado: (2021)

Rituximab in Membranous Nephropathy
por: Gauckler, Philipp, et al.
Publicado: (2021)

Membranous Nephropathy: Pilot Study of a Novel Regimen Combining Cyclosporine and Rituximab
por: Waldman, Meryl, et al.
Publicado: (2016)

An impaired hepatic clock system effects lipid metabolism in rats with nephropathy
por: Chen, Peipei, et al.
Publicado: (2018)

The role of prophylactic use of low molecular weight heparin or aspirin in thromboembolic events in primary membranous nephropathy
por: Zou, Peimei, et al.
Publicado: (2019)

Rituximab Therapy for Primary Membranous Nephropathy in a Chinese Cohort
por: Gao, Shuang, et al.
Publicado: (2021)

Clinical efficacy and safety of rituximab with membranous nephropathy: a meta-analysis
por: Zhong, Hongzhen, et al.
Publicado: (2020)

Treatment with rituximab in idiopathic membranous nephropathy
por: Fiorentino, Marco, et al.
Publicado: (2016)

Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2022)

Ectopic germinal center and megalin defect in primary Sjogren syndrome with renal Fanconi syndrome
por: Wang, Jing, et al.
Publicado: (2017)

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
por: Boyer-Suavet, Sonia, et al.
Publicado: (2020)

Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2021)

Rituximab in Primary Membranous Nephropathy With Severe CKD
por: Naik, Sachin, et al.
Publicado: (2023)

Combination of Rituximab and Low-dose Tacrolimus in the Treatment of Refractory Membranous Nephropathy: A Retrospective Cohort Study
por: Chen, Xian, et al.
Publicado: (2023)

Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience
por: Bagchi, Soumita, et al.
Publicado: (2018)

Clinicopathological features of atypical membranous nephropathy with unknown etiology in adult Chinese patients
por: Jiang, Zhenbin, et al.
Publicado: (2018)

Renal outcomes of idiopathic and atypical membranous nephropathy in adult Chinese patients: a single center retrospective cohort study
por: Jiang, Zhenbin, et al.
Publicado: (2021)

Efficacy and safety of different dosing regimens of rituximab in primary membranous nephropathy: protocol for a systematic review and meta-analysis
por: Xu, Yongxing, et al.
Publicado: (2023)

Two cases of idiopathic membranous nephropathy treated with rituximab
por: Young Yoon, Jae, et al.
Publicado: (2013)

Single-dose Rituximab Therapy for Refractory Idiopathic Membranous Nephropathy: A Single-center Experience
por: Katsuno, Takayuki, et al.
Publicado: (2017)

Rituximab for the treatment of refractory simultaneous anti-glomerular basement membrane (anti-GBM) and membranous nephropathy
por: Bandak, Ghassan, et al.
Publicado: (2014)

Divergence between serum creatine and cystatin C in estimating glomerular filtration rate of critically ill COVID-19 patients
por: Liu, Yanan, et al.
Publicado: (2021)

Association of serum mannose-binding lectin, anti-phospholipase A2 receptor antibody and renal outcomes in idiopathic membranous nephropathy and atypical membranous nephropathy: a single center retrospective cohort study
por: Zhao, Yuchao, et al.
Publicado: (2022)

Rituximab-induced serum sickness in the treatment of idiopathic membranous nephropathy
por: Cheong, Jamie, et al.
Publicado: (2018)

Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy
por: Cheungpasitporn, Wisit, et al.
Publicado: (2016)

Rituximab in Patients With Primary Membranous Nephropathy With High Immunologic Risk
por: Naik, Sachin, et al.
Publicado: (2023)

The place of cyclical therapy for the treatment of membranous nephropathy in the era of rituximab
por: Alberici, Federico, et al.
Publicado: (2023)

Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis
por: Lu, WanJun, et al.
Publicado: (2020)

Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience
por: Wang, Yao-Wei, et al.
Publicado: (2023)

Membranous nephropathy with systemic light-chain amyloidosis of remission after rituximab therapy: A case report
por: Zhang, Jiao, et al.
Publicado: (2023)

COVİD-19 infection in a membranous nephropathy patient treated with rituximab
por: Elcioglu, Omer Celal, et al.
Publicado: (2020)

Treatment of membranous nephropathy with crescent nephritis by rituximab: A case report
por: Zhang, Fan, et al.
Publicado: (2022)

Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study
por: Zhang, Shasha, et al.
Publicado: (2023)

Simplified regimen of combined low-dose rituximab for autoimmune encephalitis with neuronal surface antibodies
por: Du, Ying, et al.
Publicado: (2022)

Correction: Simplified regimen of combined low-dose rituximab for autoimmune encephalitis with neuronal surface antibodies
por: Du, Ying, et al.
Publicado: (2022)

Remission of Refractory Membranous Nephropathy by Low-dose Rituximab: A Case Report
por: Wang, Xiao-Pei, et al.
Publicado: (2016)

Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab
por: Lin, Jamie S, et al.
Publicado: (2020)

Rituximab Treatment in a Patient with Kimura Disease and Membranous Nephropathy: Case Report
por: Vissing-Uhre, Roald, et al.
Publicado: (2021)

Membranous Nephropathy with Proteinase 3-ANCA-associated Vasculitis Successfully Treated with Rituximab
por: Yoshida, Shun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o60aknats9lfh9hhluq320gqkv